Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/ct2/show/NCT03795298
Registration number
NCT03795298
Ethics application status
Date submitted
2/01/2019
Date registered
7/01/2019
Date last updated
20/05/2024
Titles & IDs
Public title
Comparison of Anticoagulation With Left Atrial Appendage Closure After AF Ablation
Query!
Scientific title
Comparison of Anticoagulation With Left Atrial Appendage Closure After AF Ablation
Query!
Secondary ID [1]
0
0
S2239
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
OPTION
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Atrial Fibrillation
0
0
Query!
Condition category
Condition code
Cardiovascular
0
0
0
0
Query!
Other cardiovascular diseases
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Devices - WATCHMAN FLX Implant
Treatment: Drugs - Market-approved OAC
Experimental: WATCHMAN FLX - WATCHMAN FLX implant including modified post-implant drug regimen.
Active Comparator: Market-approved OAC - Used per IFU for atrial fibrillation stroke prevention for the duration of the trial.
Treatment: Devices: WATCHMAN FLX Implant
Left atrial appendage closure with the WATCHMAN FLX device
Treatment: Drugs: Market-approved OAC
Used per IFU for atrial fibrillation stroke prevention for the duration of the trial.
Query!
Intervention code [1]
0
0
Treatment: Devices
Query!
Intervention code [2]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Stroke, all cause death, and systemic embolism
Query!
Assessment method [1]
0
0
WATCHMAN therapy is non-inferior for the occurrence of stroke (including ischemic and/or hemorrhagic), all cause death, and systemic embolism.
Query!
Timepoint [1]
0
0
36 months
Query!
Primary outcome [2]
0
0
Non-procedural bleeding
Query!
Assessment method [2]
0
0
WATCHMAN therapy is superior for non-procedural bleeding (ISTH major bleeding and clinically relevant non-major bleeding).
Query!
Timepoint [2]
0
0
36 months
Query!
Secondary outcome [1]
0
0
Major bleeding
Query!
Assessment method [1]
0
0
WATCHMAN therapy is non-inferior for ISTH major bleeding (including procedural bleeding).
Query!
Timepoint [1]
0
0
36 months
Query!
Eligibility
Key inclusion criteria
1. The subject is of legal age to participate in the study per the laws of their
respective geography.
2. Underwent a prior catheter ablation procedure for non-valvular AF between 90 and 180
days prior to randomization (sequential) or is planning to have clinically indicated
catheter ablation within 10 days of randomization (concomitant).
3. The subject has a calculated CHA2DS2-VASc score of 2 or greater for males or 3 or
greater for females.
4. The subject is deemed to be suitable for the defined protocol pharmacologic regimen.
5. The subject is able to undergo TEE examinations.
6. The subject or legal representative is able to understand and is willing to provide
written informed consent to participate in the trial.
7. The subject is able and willing to return for required follow-up visits and
examinations.
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
1. The subject is currently enrolled in another investigational study that would directly
interfere with the current study, except when the subject is participating in a
mandatory governmental registry, or a purely observational registry with no associated
treatments. Each instance must be brought to the attention of the sponsor to determine
eligibility, regardless of type of co-enrollment being proposed.
2. The subject requires long-term anticoagulation therapy for reasons other than
AF-related stroke risk reduction, for example due to an underlying hypercoagulable
state (i.e., even if the device is implanted, the subjects would not be eligible to
discontinue OAC due to other medical conditions requiring chronic OAC therapy).
3. The subject is deemed by the treating physician to be unsuitable for chronic
anticoagulation and/or aspirin therapy due to bleeding risk, allergy, or other
reasons.
4. The subject had or is planning to have any cardiac or major non-cardiac interventional
or surgical procedure (excluding non-valvular AF ablation and cardioversion) within 30
days prior to or 60 days after randomization [including, but not limited to:
percutaneous coronary intervention (PCI), other cardiac ablation (VT ablation, etc.),
etc.].
5. The subject had a stroke or transient ischemic attack (TIA) within the 60 days prior
to randomization.
6. The subject had a prior major bleeding event per ISTH definition within the 14 days
prior to randomization. Lack of resolution of related clinical sequelae, or planned
and pending interventions to resolve bleeding/bleeding source, are a further exclusion
regardless of timing of the bleeding event.
7. The subject has had a myocardial infarction (MI) documented in the clinical record as
either a non-ST elevation MI (NSTEMI) or as an ST-elevation MI (STEMI), with or
without intervention, within 90 days prior to randomization.
8. The subject has a history of atrial septal repair or has an ASD/PFO device.
9. The subject has an implanted mechanical valve prosthesis in any position.
10. The subject is of childbearing potential and is, or plans to become pregnant during
the time of the study (method of assessment upon study physician's discretion)
11. The subject has a documented life expectancy of less than two years.
12. The subject has a cardiac tumor.
13. The subject has signs/symptoms of acute or chronic pericarditis.
14. There is evidence of tamponade physiology.
15. Contraindications (anatomical or medical) to percutaneous catheterization procedures.
16. The subject has documented NYHA Class IV heart failure.
17. The subject has documented surgical closure of the left atrial appendage.
18. The subject has an active infection.
Query!
Study design
Purpose of the study
Prevention
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Open (masking not used)
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Not Applicable
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Active, not recruiting
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
20/05/2019
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
1/11/2024
Query!
Actual
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
1600
Query!
Recruitment in Australia
Recruitment state(s)
QLD,VIC
Query!
Recruitment hospital [1]
0
0
Advara HeartCare - Brisbane
Query!
Recruitment hospital [2]
0
0
Monash Health - Clayton
Query!
Recruitment postcode(s) [1]
0
0
4120 QLD - Brisbane
Query!
Recruitment postcode(s) [2]
0
0
3168 - Clayton
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
Alabama
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
Alaska
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
Arizona
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
Arkansas
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
California
Query!
Country [6]
0
0
United States of America
Query!
State/province [6]
0
0
Colorado
Query!
Country [7]
0
0
United States of America
Query!
State/province [7]
0
0
Connecticut
Query!
Country [8]
0
0
United States of America
Query!
State/province [8]
0
0
District of Columbia
Query!
Country [9]
0
0
United States of America
Query!
State/province [9]
0
0
Florida
Query!
Country [10]
0
0
United States of America
Query!
State/province [10]
0
0
Georgia
Query!
Country [11]
0
0
United States of America
Query!
State/province [11]
0
0
Idaho
Query!
Country [12]
0
0
United States of America
Query!
State/province [12]
0
0
Illinois
Query!
Country [13]
0
0
United States of America
Query!
State/province [13]
0
0
Indiana
Query!
Country [14]
0
0
United States of America
Query!
State/province [14]
0
0
Iowa
Query!
Country [15]
0
0
United States of America
Query!
State/province [15]
0
0
Kansas
Query!
Country [16]
0
0
United States of America
Query!
State/province [16]
0
0
Kentucky
Query!
Country [17]
0
0
United States of America
Query!
State/province [17]
0
0
Massachusetts
Query!
Country [18]
0
0
United States of America
Query!
State/province [18]
0
0
Michigan
Query!
Country [19]
0
0
United States of America
Query!
State/province [19]
0
0
Minnesota
Query!
Country [20]
0
0
United States of America
Query!
State/province [20]
0
0
Missouri
Query!
Country [21]
0
0
United States of America
Query!
State/province [21]
0
0
Nebraska
Query!
Country [22]
0
0
United States of America
Query!
State/province [22]
0
0
New Hampshire
Query!
Country [23]
0
0
United States of America
Query!
State/province [23]
0
0
New Jersey
Query!
Country [24]
0
0
United States of America
Query!
State/province [24]
0
0
New York
Query!
Country [25]
0
0
United States of America
Query!
State/province [25]
0
0
North Carolina
Query!
Country [26]
0
0
United States of America
Query!
State/province [26]
0
0
Ohio
Query!
Country [27]
0
0
United States of America
Query!
State/province [27]
0
0
Pennsylvania
Query!
Country [28]
0
0
United States of America
Query!
State/province [28]
0
0
Tennessee
Query!
Country [29]
0
0
United States of America
Query!
State/province [29]
0
0
Texas
Query!
Country [30]
0
0
United States of America
Query!
State/province [30]
0
0
Utah
Query!
Country [31]
0
0
United States of America
Query!
State/province [31]
0
0
Virginia
Query!
Country [32]
0
0
United States of America
Query!
State/province [32]
0
0
Washington
Query!
Country [33]
0
0
United States of America
Query!
State/province [33]
0
0
West Virginia
Query!
Country [34]
0
0
Belgium
Query!
State/province [34]
0
0
East Flanders
Query!
Country [35]
0
0
Denmark
Query!
State/province [35]
0
0
Aarhus
Query!
Country [36]
0
0
France
Query!
State/province [36]
0
0
Hauts-de-France
Query!
Country [37]
0
0
France
Query!
State/province [37]
0
0
Ile-de-France
Query!
Country [38]
0
0
France
Query!
State/province [38]
0
0
Clermont-Ferrand
Query!
Country [39]
0
0
France
Query!
State/province [39]
0
0
Grenoble
Query!
Country [40]
0
0
France
Query!
State/province [40]
0
0
Paris
Query!
Country [41]
0
0
France
Query!
State/province [41]
0
0
Toulouse
Query!
Country [42]
0
0
France
Query!
State/province [42]
0
0
Île-de-France
Query!
Country [43]
0
0
Germany
Query!
State/province [43]
0
0
Berlin
Query!
Country [44]
0
0
Germany
Query!
State/province [44]
0
0
Coburg
Query!
Country [45]
0
0
Germany
Query!
State/province [45]
0
0
Erfurt
Query!
Country [46]
0
0
Germany
Query!
State/province [46]
0
0
Frankfurt
Query!
Country [47]
0
0
Germany
Query!
State/province [47]
0
0
Greifswald
Query!
Country [48]
0
0
Germany
Query!
State/province [48]
0
0
Hamburg
Query!
Country [49]
0
0
Germany
Query!
State/province [49]
0
0
Leipzig
Query!
Country [50]
0
0
Germany
Query!
State/province [50]
0
0
Lübeck
Query!
Country [51]
0
0
Germany
Query!
State/province [51]
0
0
Wiesbaden
Query!
Country [52]
0
0
Italy
Query!
State/province [52]
0
0
Milano
Query!
Country [53]
0
0
Italy
Query!
State/province [53]
0
0
Torino
Query!
Country [54]
0
0
Netherlands
Query!
State/province [54]
0
0
Utrecht
Query!
Country [55]
0
0
Poland
Query!
State/province [55]
0
0
Katowice
Query!
Country [56]
0
0
Poland
Query!
State/province [56]
0
0
Poznan
Query!
Country [57]
0
0
Poland
Query!
State/province [57]
0
0
Zabrze
Query!
Country [58]
0
0
Spain
Query!
State/province [58]
0
0
Alicante
Query!
Country [59]
0
0
Spain
Query!
State/province [59]
0
0
Cadiz
Query!
Country [60]
0
0
Spain
Query!
State/province [60]
0
0
Madrid
Query!
Country [61]
0
0
Spain
Query!
State/province [61]
0
0
Pamplona
Query!
Country [62]
0
0
Spain
Query!
State/province [62]
0
0
Salamanca
Query!
Country [63]
0
0
Spain
Query!
State/province [63]
0
0
Valladolid
Query!
Country [64]
0
0
Spain
Query!
State/province [64]
0
0
Vigo
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Query!
Name
Boston Scientific Corporation
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
The primary objective of this study is to determine if left atrial appendage closure with the
WATCHMAN FLX Device is a reasonable alternative to oral anticoagulation following
percutaneous catheter ablation for high risk patients with non-valvular atrial fibrillation.
Query!
Trial website
https://clinicaltrials.gov/ct2/show/NCT03795298
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Oussama Wazni, MD
Query!
Address
0
0
The Cleveland Clinic
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Summary Results
For IPD and results data, please see
https://clinicaltrials.gov/ct2/show/NCT03795298
Download to PDF